10-7-2013

An assessment of hepatitis E virus (HEV) in US blood donors and recipients: No detectable HEV RNA in 1939 donors tested and no evidence for HEV transmission to 362 prospectively followed recipients.

Chenyu Xu  
George Washington University

Richard Y. Wang  
George Washington University

Cathy A. Schechterly  
George Washington University

Shengxiang Ge  
George Washington University

James W. Shih  
George Washington University

Recommended Citation

Authors
Chenyu Xu, Richard Y. Wang, Cathy A. Schechterly, Shengxiang Ge, James W. Shih, Ning-Shao Xia, Naomi L. Luban, and Harvey J. Alter
An assessment of hepatitis E virus (HEV) in US blood donors and recipients: no detectable HEV RNA in 1939 donors tested and no evidence for HEV transmission to 362 prospectively followed recipients

Chenyu Xu, Richard Y. Wang, Cathy A. Schechterly, Shengxiang Ge, James W. Shih, Ning-Shao Xia, Naomi L.C. Luban, and Harvey J. Alter

BACKGROUND: Hepatitis E virus (HEV) infection has become relevant to blood transfusion practice because isolated cases of blood transmission have been reported and because HEV has been found to cause chronic infection and severe liver disease in immunocompromised patients.

STUDY DESIGN AND METHODS: We tested for immunoglobulin (Ig)G and IgM antibodies to the HEV and for HEV RNA in 1939 unselected volunteer US blood donors. Subsequently, we tested the same variables in pre- and serial posttransfusion samples from 362 prospectively followed blood recipients to assess transfusion risk.

RESULTS: IgG anti-HEV seroprevalence in the total 1939 donations was 18.8%; 916 of these donations were made in 2006 at which time the seroprevalence was 21.8% and the remaining 1023 donations were in 2012 when the seroprevalence had decreased to 16.0% (p < 0.01). A significant (p < 0.001) stepwise increase in anti-HEV seroprevalence was seen with increasing age. Eight of 1939 donations (0.4%) tested anti-HEV IgM positive; no donation was HEV RNA positive. Two recipients had an apparent anti-HEV seroconversion, but temporal relationships and linked donor testing showed that these were not transfusion-transmitted HEV infections.

CONCLUSION: No transfusion-transmitted HEV infections were observed in 362 prospectively followed blood recipients despite an anti-HEV seroprevalence among donations exceeding 16%.

Hepatitis E virus (HEV) infection has been recognized as an important cause of acute, often epidemic, hepatitis in Asia and was believed to be rare in industrialized countries. However, indigenous HEV infections are increasingly reported in developed nations, and most are caused by HEV Genotypes 3 or 4 compared to Genotypes 1 and 2 that are associated with large outbreaks due to contaminated water supplies. In addition, HEV seroprevalence among blood donors and the general population in industrialized countries has been found to be much higher than expected and accumulating evidence suggests that the clinical importance of HEV infection in nonendemic regions has been underestimated. The routes of transmission in countries with safe water supplies are not well defined, although transmission from contaminated pork is possible.

ABBREVIATIONS: HEV = hepatitis E virus; LOD = limit of detection.

From the Department of Transfusion Medicine, Warren G. Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland; the National Institute of Diagnostics and Vaccine Development in Infectious Disease and the School of Public Health, Xiamen University, Xiamen, Fujian, China; and the Department of Laboratory Medicine, Center for Cancer and Blood Diseases, Children’s National Medical Center, and the Department of Pediatrics, School of Medicine and Health Sciences, George Washington University, Washington, DC.

Address reprint requests to: Harvey J. Alter, MD, MACP, Department of Transfusion Medicine, National Institutes of Health, Building 10, Room 1C-711, 10 Center Drive, Bethesda, MD 20892; e-mail: halter@dtm.cc.nih.gov.

This study was supported by Grant R01 HL67229 from the National Heart, Lung, and Blood Institute of the National Institutes of Health (NIH) and by the NIH Clinical Center Intramural Program, TRIPS Protocol 01-CC-0231.

Received for publication April 2, 2013; revision received May 28, 2013, and accepted May 28, 2013.

doi: 10.1111/trf.12326

products has been demonstrated in southwestern France and other regions.\textsuperscript{5,8–10}

The high seroprevalence of infection in asymptomatic individuals raises the potential risk of HEV transmission through blood transfusion. Although such transmission appears to be rare, a small number of transfusion-related cases have been reported and confirmed by molecular identity of the agent in donor and recipient.\textsuperscript{11–13} Importantly, this infection, once thought to be universally self-limiting, has now been shown to result in chronic infection and cirrhosis in immunocompromised patients and to exacerbate fibrosis progression and liver-related mortality in infected subjects with existing liver disease.\textsuperscript{13–15} The potential risk of blood transmission is compounded by the high proportion of blood recipients who are immunosuppressed and repeatedly transfused.

In the United States, HEV seroprevalence was found to be 21\% in a national health survey (National Health and Nutrition Survey [NHANES] III) conducted from 1988 to 1994\textsuperscript{16} and then to have fallen to 6.4\% in a similar survey (NHANES IV) conducted by the Centers for Disease Control from 2009 to 2010.\textsuperscript{17} The reason for the decrease in HEV seroprevalence between these two surveys is currently unexplained. To better assess the risk of HEV transmission by blood transfusion we investigated HEV seroprevalence among healthy US blood donors and tracked transmission rates among blood recipients enrolled in an ongoing prospective study of transfusion-transmitted infections (TRIPS). We utilized a commercial anti-HEV assay that performed well in comparative studies\textsuperscript{18} and a sensitive in-house polymerase chain reaction (PCR) assay validated with plasma from persons confirmed to have HEV Genotype 3 infection.

**MATERIALS AND METHODS**

**HEV specimens**

In our study, all tests were performed on plasma samples. In the donor study, we used unselected National Institutes of Health (NIH) volunteer blood donor samples obtained in two different time periods, specifically 2006 and 2012. In the recipient study, samples were tested before transfusion and then at 4 and/or 8 weeks posttransfusion, and at the end of the study (24 or 36 weeks posttransfusion): 21\% of recipients had a presample and three posttransfusion samples and all recipients had a presample and at least one sample obtained 8 or more weeks after transfusion. Linked donor samples were available for most recipients. Donor samples used for determination of HEV seroprevalence were not linked to specific recipients.

The TRIPS repository was initiated in November 2001 and is composed of linked donor–recipient specimens from transfusion recipients enrolled at the NIH Clinical Center (Bethesda, MD) and the Children’s National Medical Center (Washington, DC) and from Suburban Hospital (Bethesda, MD). Informed consent was obtained from all donors and recipients in accordance with the Declaration of Helsinki for participation in NIH-sponsored and institutional review board–approved protocols (NIH Protocol 01-CC-0231; Children’s National Medical Center, Protocol 2540). Human subjects were assigned a code number, and all TRIPS patient samples and both linked and unlinked donor samples were identified only by that code; the testing laboratories had no capability of linking the code number to the study participant’s name.

**Anti-HEV serology**

Anti-HEV immunoglobulin (Ig)G and IgM antibodies were detected by enzyme-linked immunosorbent assay using assays manufactured by Wantai Pharmaceutical Co., Beijing, China (research use only). This assay utilizes a recombinant peptide corresponding to open reading frame 2 (ORF2) of the HEV genome.\textsuperscript{19} According to the package insert, this assay has a specificity of 98.6\% in testing 9012 healthy Asian subjects. It is to be noted that confirmatory assays for HEV IgM and IgG antibodies are not available rendering positive findings only presumptive. Testing was performed according to the manufacturer’s instructions. Briefly, samples were diluted 1:10, added to antigen-coated plates and incubated for 30 minutes. Horseradish peroxidase conjugate was then added and followed by an additional 30 minutes of incubation. After incubation, color development was measured at an absorbance of 450 nm. Results were calculated as sample-to-cutoff ratios: values of 1.0 or above were considered reactive. Each sample was tested in duplicate and all positive samples were confirmed in a repeat duplicate assay. Only samples reactive in at least three of the four quadruplicate assays were considered positive.

**HEV RNA detection**

Pools of seven to eight donor samples were tested for HEV RNA by both real-time reverse transcription–PCR\textsuperscript{20} and a nested PCR.\textsuperscript{21} The 95\% limit of detection (LOD) for the real-time PCR assay was 400 IU/mL and the 50\% LOD was 200 IU/mL. For the nested PCR, the 95\% LOD was 200 IU/mL and the 50\% LOD was 50 IU/mL. IgM-positive samples were tested individually by both PCR methods. Nucleic acid isolation was performed using a viral RNA mini kit (QIamp, Qiagen, Chatsworth, CA) according to the manufacturer’s instructions. For real-time PCR, highly conserved sequences in the ORF3 region of all HEV genotypes were targeted: forward primer (JVHEVF: 5′-GGTGGTTTCTGGGGGTGAC-3′), reverse primer (JVHEVR: 5′-AGGGTTGGTGGATGAA-3′), and probe (JVHEVP: 5′-FAM-5′-TGGATTCTACGCCCTTCG-3′-TamRA). For nested PCR, a 150-nucleotide segment of ORF2 was amplified.
with primers E1 (5′-CTGTTTAAYCTTGCTGACAC-3′) and E5 (5′-WGARAGCCAAAGCACATC-3′) in the first round of PCR and primers E2 (5′-GACAGAATTGATTTCGTCG-3′) and E4 (5′-TGYTGGTTRTCRTAATCCTG-3′) in the second round. PCR cycling conditions for both rounds consisted of 35 cycles of denaturation at 94°C for 30 seconds, annealing at 53°C for 30 seconds, and extension at 72°C for 40 seconds. A positive HEV RNA control (200 IU/mL) was included in each assay.

Statistical analysis

All statistical analysis was performed with computer software (IBM SPSS Statistics 19, IBM Corp., Armonk, NY) where p values of less than 0.05 were considered significant.

RESULTS

Donor testing

General characteristics of the 1939 blood donations examined are summarized in Table 1. The first 916 samples were collected from January 3, 2006, to May 19, 2006. The remaining 1023 donations were collected from January 3, 2012, to March 21, 2012. HEV IgG was detected in 364 (18.8%) of the total 1939 blood donations (95% confidence interval [CI], 17.0%-20.5%). The ranges of sample-to-cutoff ratios for positive and negative samples showed a clear bimodal distribution (Fig. 1). The mean ± SD sample-to-cutoff ratio of the positive samples was 8.15 ± 5.06. The seroprevalence was 21.8% (95% CI, 19.2%-24.5%) in year 2006 samples and 16.0% (95% CI, 13.8%-18.3%) in year 2012 samples (p < 0.01).

We analyzed three demographic variables for their association with IgG seroprevalence using the samples obtained in 2006. No significant association was found in regard to sex or race (data not shown). There was a strong statistical association with age (p < 0.001): the seroprevalence of anti-HEV IgG was 3.4% (95% CI, 0.7%-6.0%) in ages below 25 and then increased linearly to 42.2% (95% CI, 31.8%-52.6%) in those over age 65 (Fig. 2). Age data were not available for samples obtained in 2012. There were eight donations that tested anti-HEV IgM reactive among the 1939 donations (0.4%). HEV RNA was not detected in any donations.

Recipient testing

The anti-HEV IgG seroprevalence of the 362 recipients in their pretransfusion samples was 21.5% (95% CI, 17.3%-25.8%) and thus very similar to the blood donor population. One recipient (0.3%) was IgM anti-HEV positive in the pretransfusion sample, but no recipient was IgM anti-HEV positive in any posttransfusion sample.
Among the 362 recipients there were two instances (0.6%) where the last posttransfusion sample was anti-HEV positive while the pretransfusion sample was anti-HEV negative. These potential anti-HEV seroconversions were further investigated. In Recipient 1, we tested all available samples from the time of transfusion to the end of study sample that tested anti-HEV positive. Each of these interim samples, obtained at 4, 12, and 20 weeks posttransfusion, tested negative for anti-HEV IgM and IgG and for HEV RNA (Fig. 3). Thus, the finding of anti-HEV in the late posttransfusion sample was an isolated, albeit reproducible finding. Next we tested linked donations: such samples were available for 69 of the 72 blood products received by this patient during the course of the study. In the 69 linked donations tested, the anti-HEV IgG seroprevalence was 14.5% (95% CI, 6.0%-23.0%). One of the IgG-positive donations was also anti-HEV IgM reactive. Four days before the recipient sample that tested anti-HEV IgG positive, this repeatedly transfused patient received blood from a donation that was HEV RNA positive by nested PCR and from a second donation that had high-titer anti-HEV (sample-to-cutoff ratio >20). Since the interval from transfusion of these HEV-reactive blood donations to the detection of anti-HEV in the recipient was only 4 days, we conclude that IgG antibody detected in the patient was passively transferred from the donated unit with high-titer anti-HEV and hence did not indicate a true seroconversion or a transfusion-associated HEV infection. Unfortunately, the patient died soon after receipt of the HEV RNA-positive blood donation so that we could not trace whether that blood unit would have transmitted HEV infection.

In the potential anti-HEV seroconversion Recipient 2, all posttransfusion samples showed low-level anti-HEV reactivity with sample-to-cutoff ratios gradually increasing from 1.5 at Week 4 to 2.5 at Week 24 posttransfusion (Fig. 3). Neither IgM anti-HEV nor HEV RNA was detected in any posttransfusion sample. Although the pretransfusion sample was below the assay cutoff and thus interpreted as negative, in retrospect it was just below the cutoff and probably the onset of an anti-HEV response that preceded study enrollment. The cause of this anti-HEV response is unknown, but we conclude that it was not related to the index transfusion in this study. None of the linked donations tested in this case had HEV markers, but we only had access to two of five donations to this patient.

These two cases illustrate the importance of having serial recipient samples and linked donations in interpreting apparent recipient seroconversion after blood transfusion. In sum, we did not observe any cases of transfusion-transmitted HEV infection among 362 prospectively followed blood recipients despite the high seroprevalence of anti-HEV IgG in our population. The observation of zero HEV infections among 362 recipients could represent a true infection rate up to 0.8% based on the upper bound of the 95% CI according to the “rule of 3.”

**DISCUSSION**

The results of our study show an anti-HEV IgG seroprevalence approaching 19% in testing 1939 blood donations. This proportion is similar to previous studies and confirms that exposure to HEV is common in the US blood donor population. Although the seroprevalence appears to have decreased over the 6-year interval between 2006 and 2012, evidence of recent or past HEV exposure remains very high. In general population surveys conducted by Centers for Disease Control and Prevention...
(NHANES), a more striking decline in anti-HEV seroprevalence was observed between 1988 to 1994 and 2009 to 2010 with a decrease from 21% to 6%. Continued monitoring of HEV seroprevalence will be important to elucidate the root causes of transmission.

Estimates of HEV seroprevalence are highly dependent on assay sensitivity and more recently employed assays appear to be both more sensitive and more specific. The anti-HEV assay utilized in this study was manufactured by Wantai Pharmaceutical Co. and is now widely used in Asia and Europe where its enhanced sensitivity has resulted in large increases in anti-HEV seroprevalence compared with earlier assays. The difference between the HEV seroprevalence observed in our study of blood donors in 2012 (16%) compared to the NHANES IV population survey in 2009 to 2010 (6%) may in part reflect test sensitivity rather than true differences in seroprevalence in the tested populations. Although preliminary studies indicate that the increased sensitivity of the Wantai assay does not come at the expense of diminished specificity, there is great need to develop HEV standards and pedigreed panels to allow valid comparisons among the competing assays to determine whether differences in seroprevalence are geographic or epidemiologic or simply assay dependent. Such panels are now under development.

No HEV viremia was detected in the approximate 2000 donations tested in this study, but this number of donations is too small to detect a low occurrence event and much larger surveys are needed. We did, however, find a small percentage of donations with IgM reactivity suggesting recent infection and posing the potential for relevant incident infections in the donor population. Indeed, although we did not find an HEV RNA–positive donation in the donor testing phase of this study, we did find an HEV RNA–positive donation when retrospectively testing linked donations to a case of potential transfusion-associated anti-HEV seroconversion. These indications of recent HEV infections in blood donors indicate the need for continued vigilance for HEV in the blood supply and the need for recipient tracing through prospective studies and lookback investigations. In our study, as in others, advancing age is a key correlate of anti-HEV seroprevalence. It is probable that this represents cumulative exposure over time, but an alternate explanation is that there is a cohort effect wherein the population had an unidentified, nonlethal HEV exposure in the remote past and the resulting antibody response has been carried forward into old age.

Sporadic cases of transfusion-related HEV infection have been reported recently and have been confirmed by molecular linkage between donor and recipient. Thus, the issue at hand is not whether HEV can be transmitted by transfusion, but rather how often and with what consequences?

In the prospective arm of our study, we tested pre- and posttransfusion samples from 362 recipients. The HEV seroprevalence of the recipients before transfusion was very similar to that of the blood donors we tested suggesting that HEV exposure and infection is widespread in the US population. Most recipients in our study received blood from at least five donations enhancing the possibility that a patient would receive blood from a donor previously infected with HEV. Based on the average transfusion number and the 0.4% seroprevalence of IgM anti-HEV, recipients in this study would have had a 1% to 2% chance of receiving blood from a recently infected, IgM-positive blood donor.

Two recipients (0.6%) among the 362 total recipients prospectively followed had an apparent anti-HEV IgG seroconversion suggesting transfusion-transmitted HEV infection. However, in one of these recipients, IgG anti-HEV was detected in only the last study sample at 36 weeks after his first within-study transfusion. No IgM antibody or HEV RNA was detected in posttransfusion samples obtained before the appearance of IgG anti-HEV. Investigation of linked donations to this repeatedly transfused recipient revealed that the patient was transfused with a strongly reactive anti-HEV–positive donation just before the detection of anti-HEV in his last follow-up sample. Thus, the antibody detected in this recipient was passively transferred and not indicative of HEV infection followed by anti-HEV seroconversion. Interestingly, the patient also received an HEV RNA–positive and an IgM anti-HEV–positive blood unit 4 days before our last study sample. The patient died soon thereafter and thus we could not trace the outcome of HEV-positive blood donations. However, this does demonstrate that HEV RNA–positive donors exist in our donor population even though none were detected in the approximate 2000 donations tested in the donor serosurvey.

In the second recipient demonstrating suspected seroconversion, retrospective testing revealed that all his posttransfusion samples were weakly reactive for anti-HEV beginning with the 4-weeks-posttransfusion sample (Fig. 3). No sample was IgM anti-HEV or HEV RNA positive. Linked donations did not reveal an HEV-infected donor, but some donations were not available for testing. Further examination of this patient’s pretransfusion sample showed that although it fell below the cutoff of the assay and hence was interpreted as anti-HEV negative, in fact, the OD reading was just below the cutoff and might have represented the onset of anti-HEV seroconversion, which then increased incrementally throughout follow-up. This scenario is compatible with an HEV exposure that occurred before the index transfusion in this study. We conclude from these two cases that neither patient was HEV infected as the result of blood transfusion administered within the time frame of the study. More importantly, we conclude that in the proper interpretation of
apparent antibody seroconversions, it is vital to examine serial recipient samples and to have linked donor samples. Access to such samples is only possible in a prospective study design.

Overall, this study concludes that past exposure to HEV is common in the US donor population, that a small proportion of such donors have IgM antibody suggestive of recent exposure, and that a very small proportion harbor HEV RNA. Thus, the potential for transfusion-transmitted HEV infection clearly exists and indeed has been confirmed in several case reports. Therefore, the issue at hand is not whether HEV can be transmitted by transfusion, but rather whether the frequency of such transmission and the clinical consequences of the infection warrant donor screening for this agent? HEV fulfills the essential criteria for an agent that might justify blood donor screening in that it can be found in asymptomatic individuals, it has been proven to be transmitted by transfusion and it can cause significant disease in immunocompromised patients who now constitute a large segment of hospitalized blood recipients. What we do not know is the magnitude of the problem and the likelihood that an asymptomatic HEV carrier would present to a donor center and be otherwise eligible to donate. Although prolonged asymptomatic viremia has been observed in immunocompromised individuals, it has not been documented in healthy blood donors. We know from studies of other blood-transmitted agents that it is the duration of asymptomatic viremia that best defines the transfusion risk. Agents such as hepatitis A virus that have an extremely brief duration of asymptomatic viremia pose little risk whereas hepatitis B virus and hepatitis C virus, which have prolonged periods of asymptomatic viremia, pose major threats and necessitate donor screening by both serology and nucleic acid testing.

Although we did not detect any transfusion-associated HEV infections among 362 prospectively followed recipients in our study, calculation of the upward bound for zero observations indicates that HEV transmission could have occurred in up to 0.8% of recipients. Further, the finding of IgM anti-HEV in the absence of HEV RNA in 0.4% of donors allows for the possibility that these donors could have been infectious had they donated days to weeks earlier when they might have been HEV RNA positive. In addition, although we did not find an HEV RNA–positive donor in a serosurvey of 1939 donors, we did detect one HEV RNA–positive donor during investigation of an apparent anti-HEV seroconversion in a recipient. Thus, it is probable that HEV–positive US blood donors will be detected when much larger serosurveys are performed. The most immediate need for the study of HEV and blood transfusion is to test tens of thousands of donors for HEV RNA and then to follow those found positive to determine the duration of viremia. If few RNA–positive donors are identified, as in our study, and if the duration of viremia in immune-competent individuals is very short, then routine donor screening will not be necessary. In contrast, if the occurrence of viremia is frequent and the duration of viremia prolonged, then donor screening would be indicated since the disease consequences in those recipients who are immune-suppressed and in those with existing liver diseases can be dire.

CONFLICT OF INTEREST

The authors declare that they have no conflicts of interest.

REFERENCES